Healthcare provider profile · identity verified

Renan R Mapue, MD

Internal Medicine · CARROLLTON, IL · NPI 1205002052

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	651	172
Amlodipine Besylate	Amlodipine Besylate	454	93
Metoprolol Succinate	Metoprolol Succinate	421	96
Levothyroxine Sodium	Levothyroxine Sodium	304	63
Omeprazole	Omeprazole	276	67
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	274	56
Hydrochlorothiazide	Hydrochlorothiazide	248	49
Pantoprazole Sodium	Pantoprazole Sodium	227	51
Gabapentin	Gabapentin	225	51
Metformin Hcl	Metformin Hcl	224	59
Tamsulosin Hcl	Tamsulosin Hcl	212	50
Meloxicam	Meloxicam	206	46
Atorvastatin Calcium	Atorvastatin Calcium	187	48
Mirtazapine	Mirtazapine	181	29
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	178	37
Losartan Potassium	Losartan Potassium	172	35
Buspirone Hcl	Buspirone Hcl	160	16
Pravastatin Sodium	Pravastatin Sodium	148	39
Bupropion Hcl Sr	Bupropion Hcl	146	29
Metoprolol Tartrate	Metoprolol Tartrate	146	26
Sertraline Hcl	Sertraline Hcl	139	16
Tramadol Hcl	Tramadol Hcl	139	33
Memantine Hcl	Memantine Hcl	138	suppressed
Glipizide Er	Glipizide	134	38
Trazodone Hcl	Trazodone Hcl	134	19
Venlafaxine Hcl	Venlafaxine Hcl	132	16
Eliquis	Apixaban	123	23
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	121	26
Lisinopril	Lisinopril	118	28
Duloxetine Hcl	Duloxetine Hcl	117	24
Farxiga	Dapagliflozin Propanediol	112	25
Spironolactone	Spironolactone	109	28
Warfarin Sodium	Warfarin Sodium	109	26
Allopurinol	Allopurinol	107	25
Isosorbide Mononitrate Er	Isosorbide Mononitrate	106	23
Pregabalin	Pregabalin	104	13
Donepezil Hcl	Donepezil Hcl	103	suppressed
Jardiance	Empagliflozin	103	18
Furosemide	Furosemide	101	35
Potassium Chloride	Potassium Chloride	100	31
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	90	23
Trulicity	Dulaglutide	87	14
Shingrix	Varicella-Zoster Ge/As01b/Pf	84	62
Famotidine	Famotidine	78	21
Diclofenac Sodium	Diclofenac Sodium	75	16
Atenolol	Atenolol	74	16
Enalapril Maleate	Enalapril Maleate	74	15
Prednisone	Prednisone	74	59
Finasteride	Finasteride	73	12
Ropinirole Hcl	Ropinirole Hcl	72	11
Doxazosin Mesylate	Doxazosin Mesylate	70	14
Clopidogrel	Clopidogrel Bisulfate	67	18
Oxybutynin Chloride	Oxybutynin Chloride	61	11
Carvedilol	Carvedilol	60	16
Albuterol Sulfate Hfa	Albuterol Sulfate	58	25
Bumetanide	Bumetanide	57	14
Montelukast Sodium	Montelukast Sodium	57	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	51	suppressed
Colestipol Hcl	Colestipol Hcl	48	suppressed
Fluticasone Propionate	Fluticasone Propionate	47	14
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	44	suppressed
Baclofen	Baclofen	43	suppressed
Chlorthalidone	Chlorthalidone	43	suppressed
Ezetimibe	Ezetimibe	42	12
Tresiba Flextouch U-200	Insulin Degludec	42	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	41	suppressed
Januvia	Sitagliptin Phosphate	39	suppressed
Hydralazine Hcl	Hydralazine Hcl	38	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	37	13
Levofloxacin	Levofloxacin	33	28
Advair Hfa	Fluticasone Propion/Salmeterol	32	suppressed
Citalopram Hbr	Citalopram Hydrobromide	30	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	30	30
Ozempic	Semaglutide	30	suppressed
Ventolin Hfa	Albuterol Sulfate	30	suppressed
Tizanidine Hcl	Tizanidine Hcl	29	18
Alendronate Sodium	Alendronate Sodium	27	suppressed
Cefuroxime	Cefuroxime Axetil	26	24
Pioglitazone Hcl	Pioglitazone Hcl	26	suppressed
Verapamil Er	Verapamil Hcl	25	suppressed
Alprazolam	Alprazolam	24	suppressed
Levetiracetam	Levetiracetam	24	suppressed
Torsemide	Torsemide	24	suppressed
Fluconazole	Fluconazole	23	16
Nitroglycerin	Nitroglycerin	23	suppressed
Tresiba Flextouch U-100	Insulin Degludec	23	suppressed
Ondansetron Hcl	Ondansetron Hcl	22	14
Creon	Lipase/Protease/Amylase	21	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	20	13
Lovastatin	Lovastatin	20	suppressed
Paroxetine Hcl	Paroxetine Hcl	20	suppressed
Valsartan	Valsartan	20	suppressed
Azithromycin	Azithromycin	19	17
Escitalopram Oxalate	Escitalopram Oxalate	18	suppressed
Trueplus Pen Needle	Pen Needle, Diabetic	17	suppressed
Celecoxib	Celecoxib	16	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	16	suppressed
Ramipril	Ramipril	16	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Enalapril-Hydrochlorothiazide	Enalapril/Hydrochlorothiazide	15	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	15	14
Topiramate	Topiramate	15	suppressed
Clonazepam	Clonazepam	14	suppressed
Dapagliflozin	Dapagliflozin Propanediol	14	11
Digoxin	Digoxin	14	suppressed
Naproxen	Naproxen	14	suppressed
Ondansetron Odt	Ondansetron	14	suppressed
Nystatin	Nystatin	13	suppressed
Testosterone Cypionate	Testosterone Cypionate	13	suppressed
Dilt-Xr	Diltiazem Hcl	12	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	12	suppressed
Gemfibrozil	Gemfibrozil	12	suppressed
Meclizine Hcl	Meclizine Hcl	12	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	12	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Cephalexin	Cephalexin	11	suppressed
Metronidazole	Metronidazole	11	suppressed
Rybelsus	Semaglutide	11	suppressed
Xarelto	Rivaroxaban	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error